Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease
Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease
复制标题
DOI：
10.1016/j.atherosclerosis.2006.08.023
复制
发表时间：
2007-10-01
期刊：
影响因子：
5.3
通讯作者：
Ogawa, Hisao
中科院分区：
文献类型：
--
作者：
Sugiyama, Seigo;Fukushima, Hironobu;Ogawa, Hisao
在接受普伐他汀治疗的患者中，2型糖尿病的发病率降低。脂联素可以对葡萄糖代谢产生有益的影响。我们研究了普伐他汀是否可以通过提高糖耐量受损(IGT)患者的脂联素水平来改善糖耐量。本研究采用口服糖耐量试验(OGTT)对40例冠心病(CAD)合并糖耐量低减(IGT)患者进行研究。患者随机分为普伐他汀治疗组(n=20)和不服用降脂药物组(对照组，n=20)，治疗6个月后重复OGTT，测定脂联素水平。普伐他汀治疗显著降低了总胆固醇(16%)、低密度脂蛋白胆固醇(23%)和高敏C反应蛋白(37%)水平(p<；0.01)。在OGTT作用2小时，普伐他汀显著改善高血糖(-14%)和高胰岛素血症(-23%)。普伐他汀治疗显著提高了血浆脂联素水平(35%；p<；0.001)，但在对照组中没有。糖耐量减低后2小时血糖降低与脂联素水平升高显著相关(r=-0.462；p=0.003)。普伐他汀治疗是改善负荷后高血糖的独立预测因子(优势比：5.7；95%可信区间1.7-19.3；p=0.003)，并实现了从糖耐量低减到正常糖耐量的有益转换(40%；p=0.03)。普伐他汀对糖代谢有良好的影响，尤其是在伴有糖耐量减低的冠心病患者的餐后状态下。(C)2006爱思唯尔爱尔兰有限公司。保留所有权利。
Reduced incidence of type-2 diabetes has been shown in patients treated with pravastatin. Adiponectin can exhibit beneficial effects on glucose metabolism. We investigated whether pravastatin could improve glucose tolerance associated with increasing adiponectin levels in patients with impaired glucose tolerance (IGT). This study consisted of 40 coronary artery disease (CAD) patients with IGT assessed by oral glucose tolerance test (OGTT). Patients were randomized to receive pravastatin (n = 20) or no lipid-lowering medications (control group, n = 20) for 6 months, after which OGTT was repeated and adiponectin levels were measured. Pravastatin treatment significantly decreased levels of total cholesterol (16%), low-density lipoprotein cholesterol (23%) and high-sensitivity C-reactive protein (37%) (p < 0.01, respectively). At 2 h in OGTT, pravastatin significantly improved hyperglycemia (-14%) and hyperinsulinemia (-23%). Pravastatin treatment significantly elevated plasma adiponectin levels (35%; p < 0.001) but not in the control group. The glucose reduction at 2 h post-OGTT was significantly associated with increased levels of adiponectin (r = -0.462; p = 0.003). Pravastatin treatment is an independent predictor for improvement of post-loaded hyperglycemia (odds ratio; 5.7; 95% confidence interval 1.7-19.3; p = 0.003) and achieved beneficial conversion from IGT to normal glucose tolerance (40%; p = 0.03). Pravastatin exhibits beneficial effects on glucose metabolism especially in the postprandial state associated with increasing plasma adiponectin levels in CAD patients with IGT. (C) 2006 Elsevier Ireland Ltd. All rights reserved.